A negative reporting bias was identified in adverse event reports after the market withdrawal of the Alcon CyPass, according to a study presented at the virtual American Academy of Ophthalmology meeting.
“With respect to the CyPass (Alcon), our work highlights that corneal and stent position-related reports increased after their clinical significance became known,” study co-author Sarah H. Van Tassel, MD, said.
Adverse events involving CyPass devices were compiled from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database through December 2019 and each
Uncategorized